CS1 Assay Portfolio Service
With professional service and various technology platforms at Creative Biolabs, we are dedicated to providing one-stop CS1 assay portfolio services to facilitate your project success.
Tumor Target CS1
CS1 molecule (also known as CD2 subunit 1, SLAMF7, CRACC, and CD319) is a type I glycoprotein receptor that belongs to the signaling lymphocytic activation molecule (SLAM) family. SLAM family molecules share a common structure, consisting of an extracellular domain with a variable (V)-type immunoglobulin (Ig)-like domain and a constant (C)2-type Ig-like domain, a single transmembrane domain, and a cytoplasmic domain with tyrosine-based motifs which undergo phosphorylation when the receptor binds to its ligand.
Fig.1 Primary structure and features of a model SLAM family receptor. (Veillette, 2013)
CS1-Targeted Therapeutics
Compared to its relatives, CS1 exhibits a unique expression pattern, with high and nearly uniform expression at the gene and protein level in myeloma cells but not in other tissues, including hematopoietic stem cells. The specificity of this expression profile makes CS1 a compelling target for immunotherapy design for multiple myeloma (MM). Currently, various CS1-targeted approaches to treat MM have been developed. such as CS1 antibodies (Elotuzumab), anti-CS1 ADCs (Azintuxizumab vedotin), CS1-targeted CAR-T cells therapy (NCT04541368).
CS1 Assay Portfolio Services
Creative Biolabs outperforms the entire biotechnological community, supporting researchers with every resource to establish the most reliable CS1 assay portfolio services to help the customer achieve incredible disproportionate results and exponentially greater value. Our CS1 assay portfolio services cover the initial target validation to the later preclinical analysis to accelerate the research process.
For more details of our CS1 assay portfolio services, please don’t hesitate to contact us for more information.
Reference
-
Veillette, A.; Guo, H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Critical reviews in oncology/hematology. 2013, 88(1): 168-77.
For Research Use Only | Not For Clinical Use
Download our brochure